Farmacross India Profile
Key Indicators
- Authorised Capital ₹ 1.50 Cr
as on 18-06-2024
- Paid Up Capital ₹ 1.01 Cr
as on 18-06-2024
- Company Age 23 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.59 M
as on 18-06-2024
- Revenue 11.21%
(FY 2023)
- Profit 33.30%
(FY 2023)
- Ebitda 35.64%
(FY 2023)
- Net Worth 34.94%
(FY 2023)
- Total Assets 44.16%
(FY 2023)
About Farmacross India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 Cr and a paid-up capital of Rs 1.01 Cr.
The company currently has active open charges totaling ₹2.59 M.
Parvin Ferzandi, Yaaresh Ferzandi, and Khushnuma Ferzandi serve as directors at the Company.
- CIN/LLPIN
U24239MH2001PTC130422
- Company No.
130422
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jan 2001
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Farmacross India?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Parvin Ferzandi  | Director | 01-Apr-2011 | Current |
| Yaaresh Ferzandi | Director | 07-Jul-2020 | Current |
| Khushnuma Ferzandi | Director | 01-Nov-2012 | Current |
Financial Performance of Farmacross India.
Farmacross India Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 11.21% increase. The company also saw a substantial improvement in profitability, with a 33.3% increase in profit. The company's net worth Soared by an impressive increase of 34.94%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Farmacross India?
In 2023, Farmacross India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Pharmacare Logistics Private LimitedActive 15 years 8 monthsParvin Ferzandi and Yaaresh Ferzandi are mutual person
Sorabji Hormusji Distributors Private LimitedActive 18 years 10 monthsParvin Ferzandi and Khushnuma Ferzandi are mutual person
Ferzandi Consulting Private LimitedActive 21 years 3 monthsParvin Ferzandi and Khushnuma Ferzandi are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Hdfc Bank Limited Creation Date: 03 Oct 2022 | ₹2.59 M | Open |
How Many Employees Work at Farmacross India?
Farmacross India has a workforce of 85 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Farmacross India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Farmacross India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
